Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871182 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00871182 is a Phase 1 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 33 participants.
The verdict
NCT00871182, a Phase 1 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary disease (COPD).
Interventions
- DRUG Inhaled Placebo
- DRUG Inhaled PT001
- DRUG Tiotropium Handihaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00871182
The ClinicalTrials.gov registry entry for NCT00871182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Inhaled Placebo is the first listed.
NCT00871182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00871182 about?
NCT00871182 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00871182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2009-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00871182?
The interventions under investigation include: Inhaled Placebo (DRUG), Inhaled PT001 (DRUG), Tiotropium Handihaler (DRUG).
Who is sponsoring clinical trial NCT00871182?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.